HALO - Halozyme raises FY20 guidance on Horizon Therapeutics global collaboration

Halozyme Therapeutics (HALO) updated FY20 financial guidance reflecting the signing of a global collaboration and license agreement with Horizon Therapeutics.FY20 revenue guidance raised to $265M to $275M (vs. $250 to $260M earlier) growing 35-40% Y/Y growth indicating anticipated revenues as Halozyme and its partners continue to execute on a number of Q4 revenue related activities.GAAP EPS of $0.90 to $0.95, increased from prior guidance of $0.80 to $0.85.Shares +0.51% PM

For further details see:

Halozyme raises FY20 guidance on Horizon Therapeutics global collaboration